The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Astra Rises On Positive Trial Results

Fri, 29th May 2020 10:59

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

AstraZeneca, up 1.9%. The drugmaker said its phase 3 Adaura trial of Tagrisso in early-stage cell lung cancer found that the drug reduced the risk of disease recurrence or death by around 80%. The detailed results were from a trial of Tagrisso, the brand name for osimertinib, after surgery in patients with "epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer after complete tumour resection with curative intent". EGFR mutations are associated with some lung cancers. In the primary endpoint of disease-free survival in patients with stage 2 and 3A disease, treatment with Tagrisso reduced risk of disease recurrence or death by 83%. Disease-free survival in the overall trial population, covering stages 1B to 3A, found a 79% drop in the risk of disease recurrence or death. At the two year mark, 89% of patients in the trial who had been treated with Tagrisso were still alive and disease free compared to a 53% figure in patients who were given a placebo.

----------

FTSE 100 - LOSERS

----------

Fresnillo, down 2.3%. The Mexican gold miner said it is responding to operational challenges caused by Covid-19 after a tough 2019. Fresnillo said it has focused on responding to the Covid-19 over the past three months, implementing a range of safety measures across the business. It confirmed that the board and senior management took voluntary and temporary pay cuts to help the company get through this "unprecedented" situation. Fresnillo said its operations are critical to the economies in which it operate, with mining now confirmed as an essential activity in Mexico. "Operationally, 2019 was a more challenging year, as expected," said Chair Alberto Bailleres. Both silver and gold production fell from 2018 levels, due to lower-than-anticipated grades in its key mines. The company said its response has been to increase the pace and scale of investments in a series of projects and take corrective actions to bring production back to acceptable levels in the short-term, and to achieve steady growth in future years.

----------

FTSE 250 - WINNERS

----------

Provident Financial, up 8.4%. The lender got an upgrade from Jefferies to Buy from Hold.

----------

B&M European Value Retail, up 4.1%. The retailer reported a strong end to the fourth quarter - which ran to March 28 - driven by an exceptionally strong March performance in Grocery, with the B&M UK fascia like-for-like revenue up 6.6%. Going forward, B&M said it experienced strong revenue growth in the first 8 weeks to May 23, with B&M UK fascia like-for-like revenue up 23%, driven by exceptionally strong Do It Yourself and Gardening categories, and despite a significant fall in customer count. If DIY and Gardening categories are excluded, the B&M UK fascia like-for-like revenue over that 8 week period was up 10%. "We have encountered exceptionally strong demand in our UK business over recent weeks. Customers have been coming to our stores much less frequently through the lockdown but their average spend has been much higher than normal," said Chief Executive Simon Arora.

----------

FTSE 250 - LOSERS

----------

Energean, down 2.0%. The oil & gas producer said its shareholder gave a green light for the name change from Energean Oil & Gas PLC to Energean PLC. In terms of trading, the company noted that it retains its strong commitment to sustainable development regardless of the impact of the global Covid-19 pandemic.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Helios Underwriting, up 9.1%. The insurance company reported profit before impairments and tax of GBP2.4 million for 2019 compared to GBP608,000 a year prior. Adjusted net asset value per share grew to GBP2.06 from GBP1.90 year-on-year. Helios said, during 2019, a further four corporate members were acquired, resulting in a 31% increase in the capacity portfolio. The four acquisitions in 2019 were purchased for a total consideration of GBP10 million, the company said. Helios said it will not be paying a dividend for 2019, having paid 3.0 pence a share in 2018. The company explained that it intends to maintain its available cash resources, given the uncertainty for the potential funding of the Covid-19 and other losses in the immediate future. "The coronavirus pandemic will be a manageable loss for the property and casualty insurance and reinsurance industry, unless there is some kind of structural change to drive the cost to the sector much higher," said Non-Executive Chair Michael Cunningham.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Johnson Service Group , down 9.3% at 129.64p. The textile services provider said it intends to raise GBP85 million through the issue of 73.9 million shares at a price of 115p. The company said the placing will be conducted through an accelerated bookbuilding process, which will be launched immediately. Investec Bank is acting as sole broker and sole bookrunner in connection with the placing. Johnson Service said it is fundraising to improve its liquidity position and further strengthen its balance sheet. The company explained that trading for the first two months of 2020, before the impact of Covid-19, was in line with its expectations, but it continues to see a significant amount of disruption across its markets. However, Johnson Service said the full implications of Covid-19 on its financial performance and position are difficult to determine at this stage.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.